Koru Medical Systems, Inc. · NASDAQ:KRMD
Koru Medical Systems — Repro Med Systems — Investor Presentation (November 2020)
18 slides from Koru Medical Systems's investor presentation, Nov 17, 2020
Slide 1: KORU Medical Systems Investor Presentation
KORU MEDICAL SYSTEMS Investor Presentation November 2020 NASDAQ: KRMD
Slide 2: Forward-Looking Statements / Non-GAAP Measures
FORWARD-LOOKING STATEMENTS / NON-GAAP MEASURES @ KORU This presentation contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as : “expect,” “plan
Slide 3: Business Profile
BUSINESS PROFILE OFor-¥: Clinical Trials Geographic Expansion Expanded Drug Indications PIDD & CIDP Patients NASDAQ: KRMD New Life, New Beginnings -3-
Slide 4: Business Profile
BUSINESS PROFILE (@ KORU Core Business / U.S. PIDD + CIDP Patients = Chronic disease state = Large addressable markets = High recurring revenue component; minimal patient churn = Growth aligned with that of Ig market Clinical Trials = Potential to significantly expand Total Addressable Market Approv
Slide 5: Putting the Patient First with Easy-to-Use Home Infusion Solutions
KORU MEDICAL SYSTEMS PUTTING THE PATIENT FIRST WITH EASY-TO-USE HOME INFUSION SOLUTIONS KORU “| am making the switch from Re +) t IVIg to SClg so | won't have Supporting the Migration Pursuing Multiple to At-Home Healthcare Growth Pathways to depend on a nurse any- more. | am excited about having mo
Slide 6: KORU's Positioning
KORU’S POSITIONING LEVERAGING OUR CORE STRENGTHS TODAY TO DRIVE GROWTH TOMORROW Gs Significant Market Share a and Growth Potential Differentiated Technology Strong Pharma Relationships Premium Customer Retention / Recurring Revenue Component Value Proposition Across The Care Continuum @®O@O® Growing
Slide 7: Our Core Business Opportunity
OUR CORE BUSINESS OPPORTUNITY (@ KORU UNDERPENETRATED MARKETS = COMPELLING GROWTH OPPORTUNITY “ees EXCLUDES OTHER DISEASE STATES AND SECONDARY IMMUNE DEFICIENCY DISEASES Total U.S. Market Penetration (KRMD) @ 500,000 ) 5% Undiagnosed U.S. PIDD Population Total U.S. _ — _ = 6,000,000 Estimated Global
Slide 8: SCIg Enables Improved Patient Outcomes and Quality of Life
SClg ENABLES IMPROVED PATIENT OUTCOMES AND QUALITY OF LIFE™ (e) KORU SClg Offers Mea OOOO gful Bene’ 's to Patients Self-administer at home without the need foranurse Infuse under the skin, not through a vein Freedom to go about daily activities with minimal interruption Consistent serum levels...wh
Slide 9: At-Home Infusion: The Savings Opportunity
AT-HOME INFUSION: THE SAVINGS OPPORTUNITY “ @ KORU Monthly Cost of Immune Deficiency Drugs for Privately Insured Individuals, 2018 [MM Hospitals [MN Physician Offices MJ Patients’ Home “For certain administered specialty drugs, treatment 44% at home can improve patients’ physical and mental well-bei
Slide 10: Core Business: Growing Number of SCIg Drugs
CORE BUSINESS: GROWING NUMBER OF SClg DRUGS (@ KORU bigots —— ar aN Une CSL Behring KORU Medical’s ae First 20% SClg therapy cleared to treat PIDD eceatteed HERTSALENE) Cleared to treat CIDP (2018) + Re Ne . and ina national advertising campaign for Collaborative approach - KORU + Pharma companies 4
Slide 11: Clinical Trials Development Pipeline
CLINICAL TRIALS DEVELOPMENT PIPELINE’ (@ KORU as Go @) Ge) Hematology Nephrology Neurology Respiratory & 2 °Y s ‘ << A IF Oncolo} Acute Care i ey " Immunology / Inflammation Pamany+ secondary, Instrumentation Immunodeficiency NASDAQ: KRMD New Life, New Beginnings -11-
Slide 12: Clinical Trial Initiatives
CLINICAL TRIAL INITIATIVES: @ KORU COMPLETED PHASE IIl HEMATOLOGY CLINICAL TRIAL USING FREEDOM SYSTEM Paroxysmal Nocturnal Hemoglobinuria (PNH) 15,000 Patients Worldwide Afflicted with PNH Fatigue 80%" » FreedomEdge Dpshogazexe- epost } Syringe Infusion Sy j SIGNS AND oaesene: “ » Renal Failure i SY
Slide 13: Geographic Expansion
GEOGRAPHIC EXPANSION Germany se Nordic Countries United Kingdom NASDAQ: KRMD New Life, New Beginnings -13-
Slide 14: 2020 Nine Month Net Sales
2020 NINE MONTH NET SALES (§ in MMs) Net Sales +19% $20.1 $16.9 9 Mos. 9 Mos. 2019 2020 NASDAQ: KRMD Core Business Clinical Trials © KORU International $15.8 $1.8 $2.6 $2.5 $13.6 F $07 9 Mos. 9 Mos. 9 Mos. 9 Mos. 9 Mos. 9 Mos. 2019 2020 2019 2020 2019 2020 New Life, New Beginnings
Slide 15: Balance Sheet and Capital Structure
BALANCE SHEET AND CAPITAL STRUCTURE $32.4M Cash & Cash Equivalents September 30, 2020 48.0M Diluted Shares Outstanding September 30, 2020 $10M S Share Repurchase Plan Authorized NASDAQ: KRMD @ KORU September 30, December 31, (S$ in millions) 2020 2019 Cash & Cash Equivalents Current Assets Total Ass
Slide 16: Investment Conclusions
INVESTMENT CONCLUSIONS Zug Secu L | Leading Product Expandable Patient Base in Market Share Core Addressable Markets Supporting Migration TY aeHomie Care Well Capitalized NASDAQ: KRMD @ KORU Y & Exploring Multiple Clinical Growth Pathways Participation YTD 2020 Adjusted EBITDA $3.9 M Cash Flow Posit
Slide 17: Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA
RECONCILIATION OF GAAP NET INCOME TO NON-GAAP ADJUSTEDEBITDA (@KORU Nine Months Ended September 30, 2020 2019 GAAP Net Income/(Loss) $ (377,435) $ 644,606 Income Tax Expense 316,200 189,265 Depreciation and Amortization 297,801 252,594 Interest Income, Net (23,690) (59,091) Reorganization Charges il
Slide 18: Thank You
THANK YOU @ KORU MEDICAL SYSTEMS NEW LIFE, NEW BEGINNINGS
Repro Med Systems — Investor Presentation (November 2020) on 6ix